전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved68 programs
AntibodyCurated CoreFDARocheApproved

glofitamab (Columvi, RO7082859, glofitamab-gxbm)

Relapsed or refractory diffuse large B-cell lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 90Status Approved
AntibodyCurated CoreFDAGenmabApproved

epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp)

Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 57Status Approved
ADCLimited DataFDAstaleRochePreclinical

Polatuzumab Vedotin-Piiq (Polatuzumab Vedotin-Piiq)

Diffuse Large B-Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Preclinical#FDA-approved#antibody-drug-conjugate+1
Trials 1Status Active
CGTLimited DatastaleTakedaPhase 1

19 (T2, 19, 19(T2)28z1xx CAR T cells)

Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Phase1#Popular#cell-gene-therapy+4
Trials 182Status Recruiting
ADCStandard DatabasestaleRochevedotin plus rituximab, cyc…Phase 2

PV (Polatuzumab vedotin, Polatuzumab vedotin (PV))

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 177Status Discontinued
AntibodyLimited DatastaleRochePhase 3

Mabthera (Mabthera)

Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 129Status Active
CGTStandard DatabasestaleShanghai Ming Ju Biotechnology …Phase 2

CD19-targeted Chimeric Antigen Receptor (CAR, CD19-targeted Chimeric Antigen Receptor, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Lymphoma, Non-Hodgkin; Diffuse Large B Cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 64Status Active
CGTStandard DatabasestaleBellicum PharmaceuticalsPhase 2

Chimeric antigen receptor (CAR, Chimeric antigen receptor, Chimeric antigen receptor (CAR) T-cell therapy)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Phase2#Popular#cell-gene-therapy+4
Trials 60Status Discontinued
CGTStandard DatabasestaleNational Cancer Institute (NCI)Phase 2

Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-CAR PBL)

Primary Mediastinal B-cell Lymphoma; Diffuse, Large B-cell Lymphoma · CD19

#CD19#CGT#Phase2#Popular#cell-gene-therapy+5
Trials 55Status Active
CGTStandard DatabasestaleKiteApproved

axicabtagene ciloleucel (Yescarta, axi-cel)

DLBCL; Diffuse Large B Cell Lymphoma · FRα

#FR#CGT#Approved#Popular#cell-gene-therapy+5
Trials 53Status Recruiting
ADCStandard DatabasestaleRochevedotin, rituximab, cycloph…Phase 2

Polatuzumab (Polatuzumab)

Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma · Lymphoma

#Lymphoma#ADC#Phase2#Popular#antibody-drug-conjugate+5
Trials 52Status Recruiting
AntibodyLimited DatastaleSeagenPhase 2

Brentuximab (Brentuximab)

Diffuse Large B Cell Lymphoma; Mediastinal Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 51Status Discontinued
AntibodyLimited DatastaleMridula George, MDPhase 2

Retifanlimab (Retifanlimab)

Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#monoclonal-antibody#AnatomicStageIVBreastCancerAJCCv+3
Trials 49Status Recruiting
ADCStandard DatabasestaleADC TherapeuticsPhase 2

Anti-CD19 Antibody-Drug Conjugate (Loncastuximab Tesirine, Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate))

Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma (HGBCL) · CD19

#CD19#ADC#Phase2#antibody-drug-conjugate#DiffuseLargeB-CellLymphoma+2
Trials 48Status Recruiting
AntibodyLimited DatastaleEpizyme, Inc.Phase 2

Tafasitamab (Tafasitamab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#monoclonal-antibody#RelapsedHematologicMalignancy+3
Trials 48Status Discontinued
CGTStandard DatabasestaleSun Yat-sen UniversityPhase 2

Relmacabtagene Autoleucel (Autoleucel, Autoleucel (Relmacabtagene Autoleucel))

Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) · Large B Cell Diffuse Lymphoma

#LargeBCellDiffuseLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 47Status Recruiting
CGTLimited DatastaleSecuraBioPhase 1

Duvelisib (Duvelisib)

Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 45Status Active
CGTStandard DatabasestaleNovartisPhase 3

tisagenlecleucel (Kymriah, tisa-cel)

DLBCL; Diffuse Large B Cell Lymphoma · FRα

#FR#CGT#Phase3#cell-gene-therapy#CAR-T+5
Trials 45Status Recruiting
CGTLimited DatastaleJuno Therapeutics, a Subsidiary…Phase 1

JCAR017 (JCAR017, JCAR017 (lisocabtagene maraleucel) 2-dose schedule, lisocabtagene maraleucel)

Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 34Status Active
AntibodyLimited DatastaleADC TherapeuticsPhase 3

Loncastuximab tesirine (Loncastuximab tesirine)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#monoclonal-antibody#RecurrentDiffuseLargeB-CellLymph+2
Trials 30Status Recruiting

1 / 4 pages

← PreviousNext →